China's Growing Role In Science - Chemical & Engineering News

Jun 23, 2014 - Eng. News Archives ... The paper documents a massive increase in China's science and technology labor force, fueled primarily by the ...
0 downloads 0 Views 347KB Size
NEWS OF TH E WEEK

CHINA’S GROWING ROLE IN SCIENCE

QUANTITY OR QUALITY China’s science and engineering labor force has grown rapidly in the past decade in comparison to that in the U.S. … Science & engineering labor force, millions 5 4

COMPETITION: Study shows country is

gaining strength but facing hurdles

EAR THAT CHINA might overtake the U.S. lead

F

in science and technology has spurred many research studies and congressional hearings. And a new analysis comparing China and U.S. science and technology data confirms that China has made impressive gains in the past decade. But the study also points out that China faces significant challenges (Proc. Natl. Acad. Sci. USA 2014, DOI: 10.1073/ pnas.1407709111). The U.S. “is not really failing from a historical point of view,” says Yu Xie, a sociologist at the University of Michigan, Ann Arbor, who led the study. However, “America as a dominant player in science may be challenged by the rise of science in other countries,” including China. The paper documents a massive increase in China’s science and technology labor force, fueled primarily by the undergraduate and graduate science degree holders the county is producing. A large increase in the number of scientific publications has ensued, Xie says. But China faces challenges in the quality of its research, which are reflected in its lower citation rates, concerns about scientific fraud, and fears the country is not scientifically creative. Xie says the massive bureaucracy that oversees universities and research institutes has led to many of these problems. For example, funding is decided by bureaucrats rather than peer review. “Chinese scientists are keenly aware of the problem,” Xie says, and they are experimenting with ways to fix it. “You can already see there is a steady improvement in quality.”—ANDREA WIDENER

Key for all graphs 3

■ U.S. 2 ■ China 1 0

1980/82a

1990

2000

2010

a U.S. data are from 1980; China’s are from 1982.

… as has China’s number of research publications … Total research articles 200,000 180,000 160,000 140,000 120,000 100,000 80,000 60,000 40,000 20,000 0 1990 92 94 96 98 00 02

04 06

08

“America as a dominant player in science may be challenged by the rise of science in other countries.”

10

… but China’s number of highly cited papers has not kept the same pace.

—YU XIE, SOCIOLOGIST, UNIVERSITY OF MICHIGAN

Top 1% of cited research articles 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 2001 02

03

04

05

06

07

08

09

10

11

SOURCE: Proc. Natl. Acad. Sci. USA

VIETNAM Novasep will build sorbitol plant as government promotes drug industry Custom pharmaceutical maker Novasep will team up with a local partner to build Vietnam’s first plant to manufacture the drug ingredient sorbitol. The project is coming together soon after Vietnam’s adoption of a new strategy to promote local production of pharmaceuticals. Novasep will build the 20,000-metricton-per-year facility in Tay Ninh province, north of Ho Chi Minh City. Although the French firm is mostly a custom manufacturer of drug ingredients, its industrial biotech business unit sells process development services, single process units,

and entire production lines to companies that make ingredients such as sorbitol and amino acids. The new sorbitol facility will be owned and operated by Tay Ninh Chemical Industry, a joint venture of Vietnam National Chemical Group and Tay Ninh Sugar. Its output will be used to make stabilizing and moistening agents for drugs, foods, and cosmetics. “This project is one of the first to emerge from Vietnam’s national development planning for pharmaceutical chemistry,” Novasep says. The plan, adopted

CEN.ACS.ORG

7

JUNE 23, 2014

in January, aims to cut costs and reduce the country’s dependence on imported drugs and drug ingredients. Vietnam imports nearly all its drug ingredients now; the policy aims for 20% local production. Pharmaceutical prices are far higher in Vietnam than elsewhere, said a recent study by Decision Resources, a health care market research firm. But foreign manufacturers attempting to sell in Vietnam face a complex regulatory environment, weak intellectual property protection, and a regionally fragmented market, the study noted.—JEAN-FRANÇOIS TREMBLAY